Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-11-23 19:14 CET (UTC+1h)

syrup hybrid application [Regulatives / Guidelines]

posted by ElMaestro - Denmark, 2017-09-06 14:44  - Posting: # 17786
Views: 679

Hi Aga,

» How could we proof equivalence for syrups, to authorise strength 5 mg/ml when only lower strength of reference product is available (2 mg/ml)? BEQ? In vitro?
» The substance is present for more than half of a century on the market and efficacy for tablet (10 and 25 mg) and syrup lower strength (2 mg/ml) is documented in the literature.

Since you use the term "hybrid" I assume you imply EU submission? If so, get a scientific advice at three agencies. You might well see that they perceive such a case completely differently among the various agencies; some might allow this as a bibliographical application, some might want you to go 10.3 and others yet may think this is something else. If you run into someone fresh out of university this could easily get impractical especially if the syrup is not a solution.

I could be wrong, but…

Best regards,

No, I still don't believe much in the usefulness of IVIVCs for OIPs when it comes to picking candidate formulations for the next trial. This is not the same as saying I don't believe in IVIVCs.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,494 Posts in 3,746 Threads, 1,090 registered users;
30 users online (0 registered, 30 guests).

Cave diving is like playing chess
but the king is not made of wood.    Jochen Hasenmayer

BEBAC Ing. Helmut Schütz